CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop novel cancer treatments by creating bioorthogonal prodrugs that release cytotoxic drugs at targeted sites. The approach utilizes palladium catalysis to activate these drugs selectively, potentially improving efficacy and reducing side effects.
The heterogeneity and capacity to evolve in response to treatment of the most aggressive forms of cancer make the selective inhibition of molecular targets an insufficient strategy to reach complete neoplastic remission.
In this context, the unspecificity of classic chemotherapeutic agents becomes an advantage for treatment.
Nonetheless, due to dose-limiting adverse effects, chemotherapeutic drugs become ineffective against some late-stage primary tumours, which are typically responsible for the…
THE UNIVERSITY OF EDINBURGH
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
